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Purpose: We studied the penetrance of pathogenically classified
variants in an elderly Dutch population from the Rotterdam Study,
for which deep phenotyping is available. We screened the 59
actionable genes for which reporting of known pathogenic variants
was recommended by the American College of Medical Genetics
and Genomics (ACMG), and demonstrate that determining what
constitutes a known pathogenic variant can be quite challenging.
Methods: We defined “known pathogenic” as classified patho-
genic by both ClinVar and the Human Gene Mutation Database
(HGMD). In 2628 individuals, we performed exome sequencing
and identified known pathogenic variants. We investigated the
clinical records of carriers and evaluated clinical events during 25
years of follow-up for evidence of variant pathogenicity.
Results: Of 3815 variants detected in the 59 ACMG genes, 17
variants were considered known pathogenic. For 14/17 variants the
ClinVar classification had changed over time. Of 24 confirmed
carriers of these variants, we observed at least one clinical event
possibly caused by the variant in only three participants (13%).
Conclusion:We show that the definition of “known pathogenic” is
often unclear and should be approached carefully. Additionally
variants marked as known pathogenic do not always have clinical
impact on their carriers. Definition and classification of true
(individual) expected pathogenic impact should be defined care-
fully.
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INTRODUCTION
Exome sequencing (ES) is of great value to detect rare,
disease-causing genetic variants in affected individuals, and is
applied in both diagnostic as well as research settings.
However, evaluating whether a variant causes the disease
can be challenging, even when this variant is predicted as
potentially pathogenic by bioinformatic tools and classified as
such in databases as the Human Gene Mutation Database
(HGMD) and/or ClinVar. Increasingly, ES is being applied to
large population-based settings with the potential to detect
incidental or secondary findings.
Given these developments, the American College of Medical
Genetics and Genomics and the Association for Molecular
Pathology (ACMG-AMP) has released a set of guidelines on
interpretation of genetic variants for clinical interpretation.1
These guidelines include evidence like variant segregation
through the affected individuals’ family, previously described
presence of other disease-causing variants in the same gene, and
knowledge of the functional mechanism of this gene in relation
to the disease. Variants are classified in five classes based on
clinical relevance: (1) benign, (2) likely benign, (3) uncertain
significance, (4) likely pathogenic, and (5) pathogenic.1 Some
databases, like ClinVar, directly follow this classification
system.2 Other databases use their own adaptation of such a
classification, such as HGMD.3
In 2013, Green et al. published a list of 56 genes involving
rare monogenetic disorders for which preventive measures
and/or treatments were available and recommended reporting
to carriers of “incidental or secondary” findings, in clinical
exome and genome sequencing data, regardless the diagnostic
implication for which the sequencing was ordered.4 This list
was updated by Kalia et al. in 2016, removing one gene and
adding four others to a total of 59 genes.5 However,
insufficient knowledge on penetrance of many variants, also
in the categories of known pathogenic (KP) or expected
pathogenic (EP) variants, makes interpretation challenging.
Since then various studies have looked into the carrier status
of pathogenic gene variants in larger and healthy populations
and how pathogenicity scores are defined by different
databases.6–10
Comparing interpretations of 99 variants of different
classifications based on the ACMG-AMP guidelines of genetic
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variants in a Mendelian disease family setting showed a 71%
to 92% agreement between 9 clinical laboratories.7 This
indicates that clinical interpretation of genetic variants for the
primary outcome (the Mendelian disease segregating in these
families) yields similar conclusions for most patients in these
diagnostic laboratories. In regard to secondary findings in
sequencing data sets from non-family-based sources, inves-
tigations of several large population studies show that between
0.7% and 3.4% of their study population participants carry a
KP or EP variant.6,8–10 Several of these studies used the
list of 56 genes initially reported by Green et al.9,10 Other
studies add additional genes considered to have a clear
phenotype–genotype relation by clinical genetic specialists,
like the 112–114 genes used by Dorschner et al. and
Amendola et al.6,8 Most studies reported KP and EP carriers,
although Amendola et al. and Jurgens et al. report respectively
0.7% and 0.9% carriers of only KP variants, suggesting almost
1% of the population carries a KP variant in the 56 ACMG
genes.6,9 Yet, these studies lack an extensive clinical follow-up
with information on health and disease status of the
participants. And so, how many of these carriers of KP or
EP variants actually have experienced clinically relevant
phenotypes due to these variants is not yet clear.
Recent studies have shown that the occurrence of KP
variants is higher in the healthy normal population than
expected based on the frequency in the Mendelian disease
patient cohorts in which these variants have been originally
identified. For example, Minikel et al. showed that the
prevalence of missense variants in the dominant prion disease
gene PRNP was 30-fold higher in the general population than
expected based on prion disease prevalence.11 A similar
observation was made for ASXL1 and other intellectual
disability genes by Ropers et al.12 On a larger scale, Saleheen
et al. showed that 1317 genes were predicted to be completely
knocked out in at least 1 of 10,503 adult Pakistani individuals,
caused by the large rate of consanguinity in this population,
but in many cases without obvious phenotype.13 Similarly,
Lek et al. showed that 3230 genes in their Exome Aggregation
Consortium database of 60,706 individuals harbored dama-
ging variants without a currently established disease pheno-
type.14 They also showed that each participant carried on
average 54 variants that might be considered pathogenic
by ClinVar or HGMD, often at higher than expected
frequencies, even for homozygous variants in genes for
recessive inheritance. Finally, Chen et al. identified 13 carriers
of severe Mendelian pathogenic variants in a large cohort of
nearly 600,000 participants,15 who did not show the expected
phenotypes and were considered nonpenetrant or resilient to
these variants. Results like these show that many potentially
pathogenic variants have a lower than expected penetrance in
healthy populations and thus should be interpreted with
caution.
In our study, we combined ES data with clinical informa-
tion of 2628 participants of the longitudinal Rotterdam Study.
This is a prospective, population-based cohort study of elderly
subjects 45 years and older, living in a suburb of Rotterdam
since 1990, and of whom we have almost 30 years of follow-
up information from clinical records and detailed physical
examination every 4–5 years.16 In the ES data we evaluated
different variant classifications for the 59 ACMG genes, using
and comparing ClinVar and HGMD to ascertain known
pathogenic variants, and then retrospectively look into the
clinical history of carriers to evaluate possible variant
pathogenicity and penetrance. Additionally, we analyzed
overall changes of variant classification over time in the
different database versions of ClinVar, in particular for the
identified known pathogenic variants observed in our study
population.
MATERIALS AND METHODS
Details on collection and processing of exome sequencing
data from the Rotterdam Study have been described
previously.17 In short, DNA of 2628 participants was
sequenced to an average depth of 56× using NimbleGen
SeqCap v2 capture and Illumina’s Hiseq2000. Data was
processed using BWA, picard, samtools and GATK. Variants
were called using GATKs HaplotypeCaller. Variants with a
variant quality over sequencing depth (QD) < 5 were filtered
out. Variants in the 59 ACMG genes were extracted and
annotated using Annovar, including minor allele frequencies
(MAFs) from the Genome Aggregation Database (gnomAD,
Karczewski et al., 2019, unpublished data), Combined
Annotation Dependent Depletion (CADD) scores, and multi-
ple versions of the ClinVar database, including the most
recently available version (2018-03-06).2,18 Variants were
annotated to HGMD (v17.3) by batch filtering in the HGMD
professional database.3 No additional filtering was performed
based on CADD score or population MAF.
Identifying known pathogenic variants
To identify KP variants in our data set we utilized the largest
and most commonly used databases of clinical interpretation
of genetic variants: the National Center for Biotechnology
Information (NCBI) ClinVar database and the Human Gene
Mutation Database (HGMD). We categorized the classifica-
tions from both databases for all variants detected in the 59
ACMG genes according to the five major classifications
outlined in the ACMG-AMP guidelines, to be able to compare
classifications in both databases.1 Specific additional evidence
criteria from ClinVar were not assessed at this point.
We added the category for absence from databases with
a zero as follows: 0: absent from database; 1: benign; 2:
likely/probable benign or likely/probably nonpathogenic; 3:
unknown, untested, or uncertain; 4: likely/probably patho-
genic; and 5: pathogenic. When multiple classifications for the
same variant were available in ClinVar, they were averaged
(e.g., a 4–4–5 variant is classified as class 4, while a 4–5–5
variant is classified as 5). HGMD classifications were coded in
a similar manner: 0: absent from database; 3: no clinical
interpretation available (NA) or functional polymorphism
(FP); 4: disease polymorphism (DP), disease functional
polymorphism (DFP), or possible disease mutation (DM?);
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and 5: disease mutation (DM). Classes 1 and 2 are not present
in HGMD. Variants classified as class 5 in both ClinVar and
HGMD were considered KP variants. All KP variants were
checked in the latest online ClinVar database (date: April
2020) to confirm the pathogenic classification for the
phenotype of which the gene was included in the ACMG
recommendations. From this time point, the ClinVar star
rating score was extracted for each variant, as well as the
number of submissions, as indicated in Table 1.
Phenotypic validation of carriers
Phenotypic events of all study participants are collected
weekly by automated linking of the general practitioners'
records and diagnoses made by medical specialists, as detailed
in the Supplemental methods. These events are compared
with all medical records, letters from medical specialists, and
discharge reports. All events were confirmed by trained
research assistants. Participants are interviewed about all
events at their next study visit.19
For each KP variant carrier, the events and respective age at
event were extracted. For each carrier of a KP variant with an
event of interest, four clinicians evaluated the potential causal
relationship between the variant and the event, giving
consideration to the age at which the event occurred. Ties
were broken by the first author. For events marked by a
majority all occurrences of this event in the data set were
collected. For each event, the average age at event and
the standard deviation were determined. The age at event of
the KP carrier was expressed as a z-score, by calculating the
number of standard deviations from the average event age
across the 2628 participants with ES data available.
Confirmation by Sanger sequencing
All carriers of KP variants classified as class 5 by both ClinVar
and HGMD were validated using Sanger sequencing. Primers
were designed and produced by Baseclear B.V. (Leiden, The
Netherlands). Optimal primer annealing temperature was
determined using gradient polymerase chain reaction (PCR)
on control DNA samples. Sanger sequencing of variants in
BRCA1/2 was performed at our department of clinical
genetics, where this is routinely performed for diagnostic
purposes. Sanger sequencing for the other variants was
performed by Baseclear B.V. Results were checked manually
to verify the variants. Primer sequences and Sanger results are
available in Supplemental results 1. Variants not confirmed by
Sanger sequencing were retained as to not bias further
interpretation (two variants in BRCA2), as is addressed in the
discussion.
Ethics statement
The Rotterdam Study has been approved by the Medical Ethics
Committee of Erasmus MC (registration number MEC 02.1015)
and by the Dutch Ministry of Health, Welfare and
Sport (Population Screening Act WBO, license number
1071272–159521-PG). This study has been entered into the
Netherlands National Trial Register (www.trialregister.nl) and
into the World Health Organization (WHO) International
Clinical Trials Registry Platform (www.who.int/ictrp/network/
primary/en/) under shared catalog number NTR6831. All
participants provided written informed consent to participate
in the study and to have their information obtained from
treating physicians.
RESULTS
Identification of known pathogenic variant carriers
Exome sequencing was performed on 2628 Rotterdam Study
(RS) participants and after filtering and quality control (QC)
resulted in a total of 703,990 genomic variants, as was
previously described.17 Of these, 3815 variants were located in
one of the 59 ACMG genes.5 All these 3815 variants were
classified using both the HGMD and ClinVar databases,
resulting in six classes—0 (absent from database), 1 (benign),
2 (likely benign), 3 (uncertain), 4 (likely pathogenic), or 5
(pathogenic)—per database.
The 3815 variants were classified and grouped according to
this system as indicated in Fig. 1, comparing their classifica-
tion in both databases. The 119 variants in autosomal
recessive genes MUTYH or ATP7B were excluded from this
figure and analyzed separately. Of the resulting 3696 variants,
935 variants (25%) were absent from both databases. An
additional 708 variants (19%) were present in HGMD but not
in ClinVar and another 481 variants (13%) were present in
ClinVar but not in HGMD. Thus, the remaining 1691 variants
(43%) were classified by both databases. Furthermore, HGMD
classifies 183 of these variants (5%) as pathogenic (class 5)
versus only 19 by ClinVar (0.5%). In total 17 variants are
classified as pathogenic by both of the databases (0.5% of all
variants), and are here defined as known pathogenic (KP)
variants. In total, 24 participants were confirmed by Sanger
validation to carry one of these 17 KP variants (0.9% of all
participants). An additional two carriers of a single variant in
BRCA2 were identified, but were found to be false positives by
Sanger validation. These variants were retained as not to bias
further interpretation, but are carefully marked in subsequent
tables.
Additionally, 8 of the 119 variants in MUTHY and ATP7B
were classified as pathogenic by both HGMD and ClinVar
(not shown), but only as autosomal recessive inheritance, thus
in homozygous state. In total, 50 carriers were observed for
any of these 8 variants, all in a heterozygous state. No
compound heterozygosity was detected. Heterozygous var-
iants in these genes were not considered as KP and thus they
were not followed up further.
Variation in ClinVar clinical classification over time
We have downloaded ClinVar database versions from the
years 2014 until 2018. For HGMD the most recent online
version was used (v17.3). Comparing the clinical classification
for the 3815 ACMG variants identified in our study
population between ClinVar database versions shows that
classification largely changes over time, as shown in Fig. 2.
First, in 2014 only 582 variants were present in ClinVar
van ROOIJ et al ARTICLE
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Annotation of ACMG variants in ClinVar (2018-06-03)
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935 172 193 116
166 457 489
Fig. 1 Classification of clinically relevant variants in 2628 Rotterdam Study participants in the 59 American College of Medical Genetics and
Genomics–Association for Molecular Pathology (ACMG-AMP) genes according to ClinVar version 2018 and the Human Gene Mutation
Database (HGMD). Classes are defined per the ACMG-AMP guidelines: (1) benign, (2) likely benign, (3) uncertain, (4) likely pathogenic, (5) pathogenic.
Variants absent from the database are coded as 0. The classifications for HGMD were converted to class 3 (No interpretation available (NA), functional
polymorphism (FP) and disease polymorphism (DP)), class 4 (disease functional polymorphism (DFP), possible disease mutations (DM?)) and class 5 (disease
mutation (DM). For visualization purposes, the variants observed in autosomal recessive genes ATP7B and MUTYH are not shown. The numbers at the sides
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Fig. 2 Classification changes of all variants detected in the 59 ACMG genes by ClinVar over time. (a) Classification of all variants detected in one of
the 59 American College of Medical Genetics and Genomics (ACMG) genes in 2628 participants of the Rotterdam Study population according to ClinVar at
different time points: March 2014 (date 140303), March 2015 (date 150330), March 2016 (date 160302), January 2017 (date 170130), and June 2018
(date 180603). Each variant is connected by a line between all five versions. Marked in yellow are the 17 known pathogenic variants classified as category 5
by the most recent versions of ClinVar (version 180603) and the Human Gene Mutation Database (HGMD) (version 17.3). (b) The number of variants in each
class of each ClinVar database version. (c) The class at each database version for the 17 variants that were classified as 5 in ClinVar in 2018 and by HGMD
17.3 (marked yellow in a). For visualization purposes, the variants observed in autosomal recessive genes ATP7B and MUTYH are not shown.
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(16%), versus 2052 in 2018 (56%), a 3.5-fold increase. This
increase was most notable for variants of class 1: benign (3.7-
fold increased), class 2: likely benign (4.5-fold increased), and
class 3: uncertain significance (3.3-fold increased). Whereas
class 5: pathogenic remained almost unchanged (1.2-fold
increase) and class 4: likely pathogenic decreased 4.1-fold
decrease). The migration of classification for the 17 known
pathogenic variants (as classified in version 2018) is marked
separately in Fig. 2. As shown, only between 5 and 7 of these
17 KP variants were classified as pathogenic at the same time
at any given ClinVar version in the previous years. In fact,
only 3 of the 17 KP variants remained at class 5 in all tested
previous versions of ClinVar. The classification per variant
per ClinVar version is indicated in Table 1. All variants were
confirmed pathogenic at the online version of ClinVar (dated
April 2020). Five of the 17 variants received a three star score
in ClinVar (reviewed by expert panel), and 10 received a two
star score (multiple submitters, no conflicting interpretation).
A single variant received a one star score (multiple submitters,
conflicting interpretation), and one variant received a zero
star score (no assertion criteria provided).
Phenotypic evaluation of known pathogenic carriers
We extracted 94 International Statistical Classification of
Diseases and Related Health Problems, Tenth Revision
(ICD10)–coded clinical events for the 26 KP carriers, from
9165 coded clinical events across our 2628 study participants,
in addition to the age at each event, shown in Fig. 3. In total,
18 events (20%) in 10 different individuals were marked by at
least one clinical referee as possibly related to the KP variant.
Nine events (10%) in three carriers (indicated with an asterisk
in Fig. 3) were marked by at least three referees.
Frequency of ICD10 events in entire study population
Nine ICD10-coded clinical events in three carriers were
considered linked to the detected variant. For each we
calculated the prevalence and average age in the rest of the
Rotterdam Study population for which we have ES data
available (n= 2628).17 The results for these nine events
are shown in Supplemental table 3. All events occurred
commonly in this population: I20: angina pectoris (in 4.9% of
the 2628 participants, average age of the event is 72 ± 8), I21:
myocardial infarction (10.5%, average age 79 ± 8), I46: cardiac
arrest (4.6%, average age 81 ± 8), I48: atrial fibrillation (19.8%,
average age 77 ± 10), I50: heart failure (24.9%, average age 80
± 8), and R99: death with cause unknown (6.3%, average age
87 ± 7). For all events selected by the referees the age at event
was earlier than the average age at event across the 2628
participants for which ES data were available, although all







































































Sanger age 60–64 age 65–69 age 70–74 age 75–79 age 80–84 age 85–89 age 90+ Associated Diseases (ACMG)
Hypertrophic cardiomyopathy, Dilated
cardiomyopathy





PTEN Hamartoma Tumor Syndrome
Romano-Ward Long QT Syndromes Types 1, 2,
and 3, Brugada Syndrome
Multiple Endocrine Neoplasia Type 2
Fig. 3 Twenty-six carriers of 17 known pathogenic (KP) variants, one shown on each line. The column “Sanger” denotes confirmed (+)
(24 samples) or unconfirmed (-) (2 samples) by Sanger sequencing. For each carrier, their recorded clinical events are displayed in 5-year intervals. The events
are coded using the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD10) classification system. The last
column denotes the primary disease for which the gene was included in the American College of Medical Genetics and Genomics (ACMG) recommen-
dations. Events marked with a “++” are evaluated by at least 3 of the 5 referees (3 of 4 clinicians or 2 clinicians and the first author) as possibly explained by
the variant for which the patient was a carrier. Those carriers are marked by an asterisk and shown in bold. Events marked with a single “+” were marked by
only 1 or 2 referees. ICD10 codes in alphabetical order: neoplasm of C18: colon, C19: rectosigmoid junction, C34: bronchus, C44: skin, C45: mesothelioma,
C50: breast, C61: prostate, C66: ureter, C67: bladder. D47: other neoplasm of uncertain behavior. F00: Alzheimer disease, F01: vascular dementia, G20:
Parkinson disease, G45: transient ischemic attack. H25: cataract, H35: retinopathy, H40: glaucoma. I20: angina pectoris, I21: myocardial infarction, I25:
ischemic heart disease, I46: cardiac arrest, I48: atrial fibrillation, I50: heart failure, I61: intercerebral hemorrhage, I63: cerebral infarct, I64: stroke, I80: deep
vein thrombosis. J15: pneumonia, J44: chronic obstructive pulmonary disease, J96: respiratory failure. M96: postprocedural skeletal disorder. R99: death of
unknown cause. Fractures of S22: rib, S32: lumbar spine, S52: forearm, S62: wrist, S72: femur, S92: foot.
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DISCUSSION
From 3815 variants that we found in 59 reported ACMG
genes in ES data of 2628 participants from the Rotterdam
Study, we confirmed 24 participants to carry a total of 17
“known” pathogenic (KP) variants, comprising 0.9% of our
study population. Two additional carriers of a single variant
in BRCA2 were identified, but this variant proved false
positive after Sanger validation, despite passing all exome
sequencing QC and filtering criteria. Upon investigation, the
variant was supported by a small number of reads and would
have been filtered out in single-sample data processing (i.e.,
the fact of two putative carriers strengthened the variant
quality in calling). Thus, this result indicates we should be
careful in the way we handle and interpret this kind of data.
Validation by Sanger sequencing in our case was required for
a reliable result. This is in line with previous findings, where
<2% of all variants identified through ES could not be
confirmed, and variants of high clinical relevance should be
confirmed beyond doubt.20,21
The proportion of 0.9% KP carriers is similar to what was
found in previous studies.6,8–10 Upon investigation by four
clinicians, 10 variant carriers (of 26) were observed with at
least one ICD10-coded clinical event deemed possibly related
to their KP variant, according to at least one of the referees.
Only in three carriers (13%) was at least one clinical event
considered to be related to the identified variant by a majority
of the referees. In all of these carriers it was difficult to
determine if the ICD10-based clinical events were caused by
these variants, as these events occur frequently in the
population. As a result, no information was reported back
to any of the carriers or their relatives.
We consulted two main databases for clinical interpretation:
HGMD and ClinVar.2,3 Comparing their clinical classification
for the ACMG variants identified in our study population we
observed disagreement in which variants are classified as
pathogenic. In total 17 variants were categorized as class 5 by
both databases, 19 in total by ClinVar, and 183 in total
by HGMD.
Of concern is a large portion of classifications that differ
between both databases, such as the 59 variants classified as
class 4 or 5 (likely pathogenic or pathogenic) in HGMD and
class 1 (benign) in ClinVar. These most likely stem
from overestimation of pathogenicity of HGMD, as has
been described before.22,23 This disagreement illustrates the
challenge of clinically interpreting genetic variants, espe-
cially in a research setting, and how different individuals,
laboratories, or databases might reach different conclusions
for the same variant. Even when restricting to variants
classified as class 5 in both databases, it appears that such
variants can be carried without obvious phenotypic
consequence.
Additionally, we investigated the clinical classification
within ClinVar in different releases over five years (from
2014 to 2018). We observe that the clinical interpretation of
many variants has changed over time, where many variants
moved toward class 1 (benign), 2 (likely benign), or 3
(uncertain significance). Over this period various genomic
variant resources have surfaced and impacted variant
interpretation, including the gnomAD database, which now
contains data from 125,748 exomes and 15,708 whole
genomes from population studies. Additionally the ACMG/
AMP criteria were released during this time frame and
influenced how consistently labs were applying evidence. One
example of this is the reclassification for BRCA1 and BRCA2
variants over time, most often downgrading.24,25 Traditionally
the classification of (pathogenic) variants was based on the
ascertainment from the more severe Mendelian disorders.
Now, with more data available from population studies,
reduced penetrance of variants is becoming clearer as is
demonstrated by these kind of variants found in individuals
without a Mendelian phenotype.11–14,26 By including infor-
mation about penetrance in healthy populations, the changes
in variant classification may stabilize over time.
Although ClinVar contributes greatly to centralizing
publicly available clinical genetic information, it does not
contain local databases maintained by clinical genetic
laboratories. This could result in classification differences of
variants between laboratories, and may challenge research
efforts to utilize clinical genetic classifications by the more
conservative ACMG-AMP criteria. Thus, our definition of a
KP variant may be less stringent than that used by a clinical
genetic laboratory. Furthermore, several of the variants we
indicated as KP have limited information available in ClinVar.
In the most recently checked online version (April 2020), two
variants had a star classification of less than 2. Five additional
variants had only one or two submissions in ClinVar at this
time. These results demonstrate the need for additional
clinical genetic information to completely classify such
variants. Nevertheless, we have attempted to retain the most
likely true pathogenic variants as possible using publicly
available information. We believe that most of these variants
would retain their pathogenic classifications under ACMG-
AMP evaluation in clinical genetic laboratories. However, it is
possible that the percentage of carriers (0.9%) and fraction of
expressivity in these carriers (13%) is lower than under
complete clinical genetic evaluation.
For the clinical evaluation of our KP carriers we used the
ICD10-coded records that report clinical events during
standard clinical practice and during Rotterdam Study
research participation. We collected 9165 ICD10-coded
events for 2628 study participants, providing unique insight
into the health of such a typical elderly population. In 0.9% of
this population we observed a KP variant, but only 13% of
these carriers (0.13% of the whole study population)
presented an ICD10-coded event that could be related to
the variant. For none of them was this effect obvious. Due to
these results, no events were reported back to any of these
carriers, and thus we were not able to collect additional, more
detailed, phenotypic information.
Our study demonstrated that the definition of a KP variant
is ambiguous between databases, but also within different
versions of the same database. This might lead to differences
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in reporting depending on the used evidence for classification.
Specifically, information on the occurrence of KP variants in
healthy populations is needed to correctly estimate the
penetrance of such variants, and this information should be
considered in the recommendations. Currently, several studies
have demonstrated that approximately 1% of the population
carries a KP defined as such by different databases. Our
results based on a thorough clinical follow-up evaluation in
subjects 55 years and older linked only 0.13% of events to the
presence of a KP variant. This suggest that KP variants are less
likely to lead to a phenotype in their carriers, and that such
reduced penetrance should be considered when reporting
back results to carriers in population-based studies. Overall,
our results indicate that reporting back of pathogenic ACMG
variants should be approached carefully in these kind of
studies.
Several causes for the reduced penetrance could play a role
in our population. First, our study population is an elderly
population, in which carriers reached late adulthood (55 years
or older) despite carrying a potentially pathogenic variant.16
Therefore, our population contains survival bias and the
penetrance of some of these variants might be higher in
younger populations. Additionally, these participants were
investigated in a research setting, and despite the rigorous
phenotype collection in the Rotterdam Study they may have
exhibited subtle clues missed during examination, such as
subclinical deviations or specific relevant family history,
which is often used in ACMG-AMP evaluation but could not
be collected in this setting. Conversely, this data set is
representative for many hospital populations in which
(secondary) genetic testing is most likely to occur.16 Second,
the expected penetrance is not standardly included in the
classification of a pathogenic variants. Thus, variants in class 5
can have variable penetrance and those variants we observe in
an elderly research population are likely those with lower
penetrance. Considering penetrance on top of the five-class
system might facilitate more accurate interpretation. Third,
such severely reduced penetrance of KP variants in
population-based settings could indicate a strong influence
of the genomic context of the functional effects of KP variants
in such normal healthy population-dwelling subjects. While
in Mendelian disease families the penetrance is usually
substantially higher, also here penetrance can be variable
and the genomic context might play a role due to the complex
way in which different inherited variants or modifiers can
influence the phenotype.27
Conclusion
We show that the definition of “known pathogenic” is often
not clear and should be approached carefully. Variants
marked as KP may have (severely) reduced penetrance.
Definition and classification of true (individual) expected
pathogenic impact should include, for example, the use of
multiple data sources, the pathogenicity prediction over time,
and an assessment of the penetrance of the variant in healthy
control populations.
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